SWOG clinical trial number
SWOG-9320

Study of ProMACE-CytaBOM with Trimethoprim Sulfamethoxazole, Granulocyte Colony Stimulating Factor (G-CSF) and Antiretroviral Therapy in Patients with AIDS Related Lymphoma, Phase II

Closed
Phase
Accrual
100%
Published
Abbreviated Title
AIDS-RELATED: ProMACE-CytaBOM w/trimethoprim sulfa, G-CSF, and antiretroviral therapy (followed by brain RT)
Activated
05/01/1994
Closed
12/01/2000
Participants
NCORP, Members, Medical Oncologists

Research committees

Lymphoma

Treatment

Radiation Therapy ProMACE-CytaBOM RT

Eligibility Criteria Expand/Collapse

Biopsy proven, non-Hodgkin's Groups D-H & J; prior diagnosis of AIDS or HIV pos.; bidimen. meas.; pts w/primary CNS lymphoma are ineligible; no prior chemo or RT; no hx of cardiac impairment.

Publication Information Expand/Collapse

2003

Phase II study of pro-MACE CytaBOM with trimethoprim sulfamethoxazole, granulocyte colony stimulating factor (G-CSF) and antiretroviral therapy in patients with AIDS related non-Hodgkin's lymphoma (AIDS-NHL), (S9320)

LJ Swinnen;E Gaynor;M LeBlanc;MJ Lechowicz;J Unger;TP Miller;TM Grogan;RI Fisher Blood 102(11):(#1462)

1999

Frequent expression of hte tumor necrosis factor receptor associated factor-1 in LMP1-positive post transplant lymphoproliferative disease and HIV-associated lymphomas

PG Murray;LJ Swinnen;JR Flavell;MV Ragni;HT Hassan;D Lowe;C Schnell;J Johl;LS Young;RF Ambinder Blood 94(10)Suppl.1:303a(#1353)part_1_of_2

Other Clinical Trials

SWOG Clinical Trial Number
S2308

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
12%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase